



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/033,195	12/28/2001	Stephen P.A. Fodor	2719.2002-001	7969
HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 VIRGINIA ROAD P.O. BOX 9133 CONCORD, MA 01742			EXAMINER	
			RILEY, JEZIA	
			ART UNIT	PAPER NUMBER
			1637	
			DATE MAIL ED: 12/15/200/	

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)					
	10/033,195	FODOR ET AL.					
Office Action Summary	Examiner	Art Unit					
	Jezia Riley	1637					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on <u>01 N</u>	1) Responsive to communication(s) filed on <u>01 November 2004</u> .						
2a) ☐ This action is FINAL . 2b) ☒ This action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>57-73</u> is/are pending in the application.							
4a) Of the above claim(s) <u>74</u> is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>57-74</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>57-74</u> are subject to restriction and/or	8) Claim(s) 57-74 are subject to restriction and/or election requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10)⊠ The drawing(s) filed on <u>28 December 2001</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12)□ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau	ı (PCT Rule 17.2(a)).	ű					
* See the attached detailed Office action for a list of the certified copies not received.							
	,						
Attachment(s)							
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date Notice of Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Notice of Informal Patent Application (PTO-152)							
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 11/5/04; 1/8/04; 1/8/04 5) Notice of Informal Patent Application (PTO-152) 6) Other:							
U.S. Patent and Trademark Office	tion Summary Pa	art of Paper No./Mail Date 20041208					

Art Unit: 1637

DETAILED ACTION

Applicant's election without traverse of Group I in the reply filed on 11/1/04 is acknowledged.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 71-73 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 71 is directed to a method for preparing a compound of claim 57, comprising attaching a photoremovable group to C-3' or C-5' oxygen atom of a nucleoside and subsequently attaching an activated phosphorous group. There is not description in the specification of a method where the photoremovable protecting group is attached to the nucleoside before attaching an activated phosphorous group (see page 51).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11

Application/Control Number: 10/033,195

Art Unit: 1637

F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 57-70 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-37, 39 of U.S. Patent No. 5,753,788. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are both claiming compounds comprising a photoremovable protecting group covalently attached to a nucleoside at the 3' or 5'-position. Said nucleoside can comprise an activated phosphorous group. (see claims and col. 27-28).

Claims 57-65 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 5, 7-13, 16-21 of U.S. Patent No. 5,889.165. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are claiming compounds comprising a photoremovable protecting group covalently attached to a nucleoside at the 3' or 5'-position. Said nucleoside can comprise an activated phosphorous group. (see claims and col. 27-28).

Claims 57-70 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 6,310,189. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are claiming compounds comprising a photoremovable protecting group covalently attached to a nucleoside at the 3' or 5'-position. Said nucleoside can comprise an activated phosphorous group.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 571-272-0786. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Wednesday, December 08, 2004

/ JEZIA RILEY PRIMARY EXAMINER